<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03465644</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2018-03</org_study_id>
    <nct_id>NCT03465644</nct_id>
  </id_info>
  <brief_title>TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI</brief_title>
  <acronym>TAILORED-CHIP</acronym>
  <official_title>Comparison of Tailored Antiplatelet Therapy With Early Escalation and Late De-Escalation Strategy Versus Standard Dual Antiplatelet Therapy in Patients Undergoing Complex High-Risk Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duk-Woo Park, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of tailored antithrombotic therapy with early
      (&lt;6-month post-PCI) intensified (low-dose ticagrelor [120 mg loading, then 60 mg bid
      maintenance] and aspirin) and late (&gt;6-month post-PCI) deescalated (clopidogrel alone)
      strategy in patients undergoing high-risk complex PCI as compared with standard Dual
      Antiplatelet Therapy(aspirin and clopidogrel for 12 months).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net clinical outcome</measure>
    <time_frame>1 year</time_frame>
    <description>a net clinical outcome of all-cause death, MI, stroke, stent thrombosis, urgent revascularization and clinically relevant bleeding [Bleeding Academic Research Consortium (BARC) 2, 3, or 5] at 12 months post-PCI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgent revascularization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically relevant bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>Bleeding Academic Research Consortium (BARC) 2, 3, or 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of death (all or cardiovascular), MI, or stroke, stent thrombosis or urgent revascularization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of death (all or cardiovascular), MI, or stroke</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of death (all or cardiovascular) or MI</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any revascularization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BARC type 3 or 5 bleeding</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major or minor bleeding according to definitions from The Thrombolysis in Myocardial Infarction (TIMI)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major or minor bleeding according to definitions from International Society of Thrombosis or Hemostasis (ISTH)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Coronary Stenoses</condition>
  <arm_group>
    <arm_group_label>Tailored arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>early (&lt;6-month post-PCI) intensified (low-dose ticagrelor [120 mg loading, then 60 mg bid maintenance] and aspirin) and late (&gt;6-month post-PCI) deescalated (clopidogrel alone) strategy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clopidogrel + aspirin for 12months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tailored antithrombotic strategy</intervention_name>
    <description>Low-dose (60mg) ticagrelor + aspirin for 6months and then clopidogrel alone for 6months</description>
    <arm_group_label>Tailored arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional antithrombotic strategy</intervention_name>
    <description>Clopidogrel + aspirin for 12months</description>
    <arm_group_label>Conventional arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 19 and more

          -  Successful percutaneous coronary intervention(PCI) with contemporary drug-eluting
             stent

          -  at least one of the following high-risk clinical, lesion or procedure-related risk
             factors;

          -  Clinical factors: diabetes, chronic kidney disease (i.e. creatinine clearance &lt;60
             mL/min), or low left ventricular ejection fraction (&lt;40%) or

          -  Lesion- or procedure-related factors: left main PCI, chronic total occlusion,
             bifurcation with 2 stents implanted, severe calcification, diffuse long lesion (lesion
             length ≥ at least 30 mm), multi-vessel PCI (≥ 2 vessels stented), ≥3 stents implanted,
             ≥ 3 lesions treated, or total stent length &gt; 60 mm

        Exclusion Criteria:

          -  Enzyme-positive ACS (NSTEMI or STEMI)

          -  Contraindication to aspirin or P2Y12 inhibitors (ticagrelor or clopidogrel)

          -  Cardiogenic shock at the index admission

          -  Treated with only bare metal stent or balloon angioplasty during the index procedure

          -  Need for chronic oral anticoagulation

          -  Active bleeding or extreme-risk for major bleeding (e.g. active peptic ulcer disease,
             gastrointestinal pathology with a high risk for bleeding, malignancies with a high
             risk for bleeding)

          -  History of intracranial haemorrhage or intracranial aneurysm

          -  Planned surgery within 180 days

          -  Liver cirrhosis

          -  Dialysis-dependent renal failure

          -  Pregnant and/or lactating women

          -  Concurrent medical condition with a life expectancy of less than 1 years

          -  Patients who are actively participating in another drug or device investigational
             study, which have not completed the primary endpoint follow-up period

          -  Unable to provide written informed consent or participate in long-term follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Duk-woo Park, MD</last_name>
    <email>dwpark@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jung-hwa Lee, RN</last_name>
    <phone>82230104734</phone>
    <email>nurse9726@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <last_update_submitted>April 1, 2018</last_update_submitted>
  <last_update_submitted_qc>April 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Duk-Woo Park, MD</investigator_full_name>
    <investigator_title>Professor, Division of Cardiology</investigator_title>
  </responsible_party>
  <keyword>antithrombotic strategy</keyword>
  <keyword>dual antiplatelet therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

